Yüklüyor......
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
BACKGROUND/AIMS: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to...
Kaydedildi:
| Yayımlandı: | Korean J Intern Med |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
The Korean Association of Internal Medicine
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6823557/ https://ncbi.nlm.nih.gov/pubmed/30360024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2018.144 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|